デフォルト表紙
市場調査レポート
商品コード
1440026

抗精神病薬の世界市場:洞察、競合情勢、市場予測:2030年

Antipsychotic Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
抗精神病薬の世界市場:洞察、競合情勢、市場予測:2030年
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗精神病薬の市場規模は、2022年に134億476万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に6.62%のCAGRで拡大し、2030年には196億5,329万米ドルに達すると予測されています。抗精神病薬市場は、統合失調症、統合失調感情障害、双極性障害、重度のうつ病、人格障害の精神病症状などの精神障害の有病率の上昇により、大幅な市場成長を遂げています。さらに、精神障害に罹患しやすい高齢者人口の増加、メンタルヘルスに対する政府やヘルスケア機関の関心の高まり、長時間作用型注射剤に対する需要の高まりなどが、抗精神病薬の需要急増に寄与しています。同様に、研究開発活動の活発化、薬剤の承認・上市の急増、市場における主要参入企業の存在は、抗精神病薬の必要性を市場にもたらすとみられています。

世界保健機関(WHO)2022によると、2019年には世界中で8人に1人、9億7,000万人が精神障害を抱えて生活しており、不安障害とうつ病性障害が最も一般的であると述べています。2020年には、COVID-19の大流行により、不安障害とうつ病性障害と暮らす人の数が大幅に増加しました。

さらに、前述の2022年の情報源は、うつ病は世界的に一般的な病気であり、人口の3.8%が罹患していると推定され、そのうち成人では5.0%、60歳以上の高齢者では5.7%が罹患していると述べています。この情報源は、2019年には世界で約2億8,000万人がうつ病を患っていると述べています。

2022年のWHOは、2019年には約4,000万人が双極性障害を経験し、子どもや青年を含む約4,000万人が行為非社会性障害を抱えていると述べています。

したがって、上記の統計から、精神障害の有病率は世界中で非常に高く、最終的に上記の障害の治療に従事する抗精神病薬の需要を増大させていると結論づけることができます。

当レポートでは、世界の抗精神病薬市場について調査し、市場の概要とともに、適応症別、薬剤クラス別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 抗精神病薬市場レポートのイントロダクション

第2章 抗精神病薬市場のエグゼクティブサマリー

第3章 規制分析

第4章 抗精神病薬市場の主な要因分析

  • 抗精神病薬市場の促進要因
  • 抗精神病薬市場の抑制要因と課題
  • 抗精神病薬市場の機会

第5章 抗精神病薬市場におけるポーターのファイブフォース分析

第6章 抗精神病薬市場へのCOVID-19の影響分析

第7章 抗精神病薬市場の概要

  • 適応症別
  • 薬剤クラス別
  • 流通チャネル別
  • 地域別

第8章 抗精神病薬市場の企業と製品プロファイル

  • Eli Lily and Company
  • Janssen Global Services, LLC,
  • Pfizer Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Alkermes, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • AbbVie Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals LLC.
  • Alvogen.
  • Hikma Pharmaceuticals PLC
  • Viatris Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cardinal Health Inc.
  • Sanis Health Inc.
  • H. Lundbeck A/S
  • Elikem Pharmaceuticals Pvt Ltd
  • Devlife Corporation Private Limited.
  • GSK plc.

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on Antipsychotic Drugs Market
  • Table 3: Antipsychotic Drugs Market Analysis in Global (2021-2030)
  • Table 4: Antipsychotic Drugs Market Analysis in Global by Indication (2021-2030)
  • Table 5: Antipsychotic Drugs Market Analysis in Global by Drug Class (2021-2030)
  • Table 6: Antipsychotic Drugs Market Analysis in Global by Distribution Channel (2021-2030)
  • Table 7: Antipsychotic Drugs Market Analysis in Global by Geography (2021-2030)
  • Table 8: Antipsychotic Drugs Market Analysis in North America (2021-2030)
  • Table 9: Antipsychotic Drugs Market Analysis in North America by Country (2021-2030)
  • Table 10: Antipsychotic Drugs Market Analysis in the US (2021-2030)
  • Table 11: Antipsychotic Drugs Market Analysis in Canada (2021-2030)
  • Table 12: Antipsychotic Drugs Market Analysis in Mexico (2021-2030)
  • Table 13: Antipsychotic Drugs Market Analysis in Europe (2021-2030)
  • Table 14: Antipsychotic Drugs Market Analysis in Europe by Country (2021-2030)
  • Table 15: Antipsychotic Drugs Market Analysis in France (2021-2030)
  • Table 16: Antipsychotic Drugs Market Analysis in Germany (2021-2030)
  • Table 17: Antipsychotic Drugs Market Analysis in the UK (2021-2030)
  • Table 18: Antipsychotic Drugs Market Analysis in Italy (2021-2030)
  • Table 19: Antipsychotic Drugs Market Analysis in Spain (2021-2030)
  • Table 20: Antipsychotic Drugs Market Analysis in the Rest of Europe (2021-2030)
  • Table 21: Antipsychotic Drugs Market Analysis in Asia-Pacific (2021-2030)
  • Table 22: Antipsychotic Drugs Market Analysis in Asia-Pacific by Country (2021-2030)
  • Table 23: Antipsychotic Drugs Market Analysis in China (2021-2030)
  • Table 24: Antipsychotic Drugs Market Analysis in Japan (2021-2030)
  • Table 25: Antipsychotic Drugs Market Analysis in India (2021-2030)
  • Table 26: Antipsychotic Drugs Market Analysis in Australia (2021-2030)
  • Table 27: Antipsychotic Drugs Market Analysis in South Korea (2021-2030)
  • Table 28: Antipsychotic Drugs Market Analysis in the Rest of Asia-Pacific (2021-2030)
  • Table 29: Antipsychotic Drugs Market Analysis in the Rest of the World (2021-2030)
  • Table 30: Antipsychotic Drugs Market Analysis in the Rest of the World by Region (2021-2030)
  • Table 31: Antipsychotic Drugs Market Analysis in the Middle East (2021-2030)
  • Table 32: Antipsychotic Drugs Market Analysis in Africa (2021-2030)
  • Table 33: Antipsychotic Drugs Market Analysis in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis on Antipsychotic Drugs Market
  • Figure 3: Antipsychotic Drugs Market Analysis in Global (2021-2030)
  • Figure 4: Antipsychotic Drugs Market Analysis in Global by Indication (2021-2030)
  • Figure 5: Antipsychotic Drugs Market Analysis in Global by Drug Class (2021-2030)
  • Figure 6: Antipsychotic Drugs Market Analysis in Global by Distribution Channel (2021-2030)
  • Figure 7: Antipsychotic Drugs Market Analysis in Global by Geography (2021-2030)
  • Figure 8: Antipsychotic Drugs Market Analysis in North America (2021-2030)
  • Figure 9: Antipsychotic Drugs Market Analysis in North America by Country (2021-2030)
  • Figure 10: Antipsychotic Drugs Market Analysis in the US (2021-2030)
  • Figure 11: Antipsychotic Drugs Market Analysis in Canada (2021-2030)
  • Figure 12: Antipsychotic Drugs Market Analysis in Mexico (2021-2030)
  • Figure 13: Antipsychotic Drugs Market Analysis in Europe (2021-2030)
  • Figure 14: Antipsychotic Drugs Market Analysis in Europe by Country (2021-2030)
  • Figure 15: Antipsychotic Drugs Market Analysis in France (2021-2030)
  • Figure 16: Antipsychotic Drugs Market Analysis in Germany (2021-2030)
  • Figure 17: Antipsychotic Drugs Market Analysis in the UK (2021-2030)
  • Figure 18: Antipsychotic Drugs Market Analysis in Italy (2021-2030)
  • Figure 19: Antipsychotic Drugs Market Analysis in Spain (2021-2030)
  • Figure 20: Antipsychotic Drugs Market Analysis in the Rest of Europe (2021-2030)
  • Figure 21: Antipsychotic Drugs Market Analysis in Asia-Pacific (2021-2030)
  • Figure 22: Antipsychotic Drugs Market Analysis in Asia-Pacific by Country (2021-2030)
  • Figure 23: Antipsychotic Drugs Market Analysis in China (2021-2030)
  • Figure 24: Antipsychotic Drugs Market Analysis in Japan (2021-2030)
  • Figure 25: Antipsychotic Drugs Market Analysis in India (2021-2030)
  • Figure 26: Antipsychotic Drugs Market Analysis in Australia (2021-2030)
  • Figure 27: Antipsychotic Drugs Market Analysis in South Korea (2021-2030)
  • Figure 28: Antipsychotic Drugs Market Analysis in the Rest of Asia-Pacific (2021-2030)
  • Figure 29: Antipsychotic Drugs Market Analysis in the Rest of the World (2021-2030)
  • Figure 30: Antipsychotic Drugs Market Analysis in the Rest of the World by Region (2021-2030)
  • Figure 31: Antipsychotic Drugs Market Analysis in the Middle East (2021-2030)
  • Figure 32: Antipsychotic Drugs Market Analysis in Africa (2021-2030)
  • Figure 33: Antipsychotic Drugs Market Analysis in South America (2021-2030)
  • Figure 34: Market Drivers
  • Figure 35: Market Barriers
  • Figure 36: Market Opportunities
  • Figure 37: PORTER's Five Force Analysis
目次
Product Code: DISR0065

Antipsychotic Drugs Market By Indication (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, And Others), By Drug Class (First Generation Or Typical Antipsychotics [Haloperidol, Prochlorperazine, And Others], Second Generation Or Atypical Antipsychotics [Clozapine, Risperidone, And Others], Third Generation [Abilify And Others], By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, And E-Commerce), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing burden of mental disorders such as schizophrenia, dementia, and others and the increasing research & developmental activities concerning to the antipsychotic drugs across the globe

The global antipsychotic drugs market was valued at USD 13,404.76 million in 2022 and is likely to register a CAGR of 6.62% during the forecast period from 2024 to 2030 to reach USD 19,653.29 million by 2030. The antipsychotic drugs market is observing substantial market growth due to the growing prevalence of mental disorders such as schizophrenia, schizoaffective disorder, bipolar disorder, severe depression, psychotic symptoms of a personality disorder, and others. Further, the increasing geriatric population base prone to mental disorders, the increasing focus of governments and healthcare organizations on mental health, the increasing demand for long-acting injectables, and others will aid in surging the demand for antipsychotic drugs. Likewise, the increasing research & developmental activities along with the surging drug approvals and launches and the presence of key players in the market will create a requisite for antipsychotic drugs in the market. Therefore, the market for antipsychotic drugs is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Antipsychotic Drugs Market Dynamics:

According to the World Health Organization (WHO) 2022, stated that in 2019, 1 in every 8 people, or 970 million people around the world were living with a mental disorder, with anxiety and depressive disorders the most common. In 2020, the number of people living with anxiety and depressive disorders rose significantly because of the COVID-19 pandemic.

Further, the afore-mentioned source in 2022 stated that depression is a common illness worldwide, with an estimated 3.8% of the population affected, including 5.0% among adults and 5.7% among adults older than 60 years. The source mentioned that approximately 280 million people in the world had depression, in 2019.

The WHO in 2022 stated that nearly 40 million people experienced bipolar disorder and nearly 40 million people, including children and adolescents, were living with conduct-dissocial disorder in 2019.

Thus, from the above statistics, it can be concluded that the prevalence of mental disorders is very high across the globe, ultimately increasing the demand for antipsychotic drugs, engaged in the treatment of the above-mentioned disorders.

Additionally, there have been numerous research and development initiatives aimed at the development of these medications in recent years. R&D activities are carried out to improve the safety and efficacy of such drugs. Also, the increased awareness led to greater adoption of these drugs in key countries, significantly increasing market growth in key countries.

Moreover, the clinical trials of antipsychotic drugs are expected to significantly advance the drug development process. For instance, Karuna Therapeutics is advancing its product pipeline by introducing novel drug candidates such as KarXT (xanomeline-trospium) for the treatment of various psychiatric and neurological conditions. Currently, the candidate is being evaluated in late-stage clinical trials as a potential treatment for schizophrenia and psychosis in Alzheimer's disease. In October 2022, the company also announced the data of the Phase III clinical trial.

Thus, the surging awareness, united with the new launches based on innovative R&D, is expected to drive the market growth for antipsychotic drugs during the forecast period 2022 - 2028.

Therefore, the factors stated above collectively will drive the overall antipsychotic drugs market throughout the forecast period from 2024-2030.

However, the high cost of drug development and launches, addiction caused due to antipsychotic drugs, and stringent regulatory approval process may halt the market growth of antipsychotic drugs.

The antipsychotic drugs market was moderately impacted during the period of COVID- 19 pandemic. During the initial stage of the pandemic, the sale of antipsychotics suffered collapse owing to the imposition of strict lockdown rules, disruption in manufacturing, and supply. However, the government classified medicines and drugs under emergency products during the pandemic, thereby leading to an increase in their demand or sales. Moreover, with the involvement of online pharmacies, the sale of many over-the-counter medicines increased, impacting the market for antipsychotic drugs. Also, the pandemic attributed to the greater adoption of Long-Acting injectables (LAIs) during the pandemic. For instance, Otsuka Pharmaceutical Co. Ltd.'s drug, ABILIFY MAINTENA, a LAI witnessed an increase of 13.9% in its revenue in 2020 compared to 2019. Likewise, the ease of lockdown restrictions, the upturn of resources and supply chain, the administration of a vaccine to the public, and with the increasing number of treatment rates for mental disorders, the demand for antipsychotic drugs increases and is anticipated to do the same during the forecast period from 2022 - 2028.

Antipsychotic Drugs Market Segment Analysis:

Antipsychotic Drugs Market by Indication (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, and Others), Drug Class (First Generation or Typical Antipsychotics [Haloperidol, Prochlorperazine, and Others], Second Generation or Atypical Antipsychotics [Clozapine, Risperidone, and Others], Third Generation [Abilify and Others], Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the indication segment of the antipsychotic drugs market, the schizophrenia segment is expected to have a significant revenue share in the year 2023. This was primarily owing to the increasing prevalence of schizophrenia across the globe. Also, the expanding launches and strategic investments, and other activities by the key players related to the segment will support the market growth during the forecast period.

For instance, the source WHO in 2022 statistics, added that schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) worldwide and this rate is 1 in 222 people (0.45%) among adults, in 2019. Moreover, onset is most often during late adolescence and the twenties, and the onset tends to happen earlier among men than among women.

Further, as per the latest study done by National Alliance on Mental Illness, nearly 1.5 million people yearly suffer from schizophrenia, in the United States. The same source stated that at some time during their life about 1 in 100 people will suffer an episode of schizophrenia.

Moreover, the presence of a robust number of schizophrenia-treating antipsychotic drugs in the pipeline will drive market growth. For instance, in February 2022, Alkermes plc received positive results from ENLIGHTEN-Early, a phase 3b study that assessed the effect of LYBALVI (olanzapine and samidorphan) compared to olanzapine on body weight in young adult patients (ages 16 to 39; mean age: 26 years) with schizophrenia, schizophreniform disorder or bipolar I disorder.

Further, various other strategic steps taken by key players in the market will help in driving the growth of antipsychotics. For instance, in January 2022, Otsuka America Pharmaceutical, Inc. and H. Lundbeck A/S received the U.S. FDA approval for the supplemental new drug application (sNDA) of REXULTI (brexpiprazole) for the treatment of schizophrenia in pediatric patients from the ages 13 to 17.

Therefore, owing to the above-mentioned factors, the demand for schizophrenia-treating antipsychotic drugs upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the global antipsychotic drugs market during the forecast period.

North America is expected to dominate the overall Antipsychotic Drugs Market:

Among all the regions, North America is expected to dominate the global antipsychotic drugs in the year 2023 and is expected to do the same during the forecast period from 2024-2030.

This can be ascribed to the increasing demand for antipsychotic drugs in the region owing to the increasing prevalence of various mental disorders in the region. Further, the rising burden of geriatric patients, the presence of key domicile players in the region, surging drugs approvals and launches, and others are among the key factors that contribute to the growth of the antipsychotic drugs market in North America during the forecast period from 2022 - 2028.

For instance, as per the latest study conducted by the National Alliance on Mental Illness, 1 in 5 US adults experience mental illness each year and 1 in 20 US adults experience serious mental illness each year. Further, 1 in 6 US youth aged 6-17 experience a mental health disorder each year.

Additionally, as per the source Depression and Bipolar Support Alliance 2022, bipolar disorder affects approximately 5.7 million adult Americans, or about 2.6% of the US population aged 18 and older every year.

Thus, the rising prevalence of mental disorders such as bipolar disorder, dementia, depression, and others will propel the demand for antipsychotic drugs during the forecast period.

Additionally, the rising burden of geriatric patients prone to mental disorders is also going to propel the demand for antipsychotic drugs in the region.

Furthermore, the increasing activities by the key players in the region will in turn increase the demand for the product during the forecast period. For instance, in June 2020, Neurocrine Biosciences entered into a strategic collaboration with Takeda Pharmaceuticals to develop and commercialize compounds in Takeda's early-to-mid-stage psychiatry pipeline. Under the collaboration, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical-stage assets for schizophrenia, treatment-resistant depression, and anhedonia.

Moreover, the market players in the country are continuously concentrating on the development of novel drugs to tackle mental disorders indications using antipsychotic drugs, and they are also adopting various strategies to develop better drugs with reduced side effects. Thus, this is likely to drive the market in the region. For instance, in September 2022, Zydus Lifesciences' US subsidiary Zydus Pharmaceuticals (USA) Inc. received final approval from the United States Food and Drug Administration (USFDA) to market Cariprazine Capsules, USP 1.5 mg, 3 mg, 4.5 mg, and 6 mg. Cariprazine is an atypical antipsychotic indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder.

Therefore, the interplay of the aforementioned factors would provide a conducive growth environment for the North America region in the antipsychotic drugs market.

Antipsychotic Drugs Market Key Players:

Some of the key market players operating in the antipsychotic drugs market include Eli Lily and Company, Janssen Global Services, LLC, Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Alkermes, Inc., Dr. Reddy's Laboratories Ltd., AbbVie Inc., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., Alvogen., Hikma Pharmaceuticals PLC, Viatris Inc., Bayer AG, Bristol-Myers Squibb Company, Cardinal Health Inc., Sanis Health Inc., H. Lundbeck A/S, Elikem Pharmaceuticals Pvt Ltd, Devlife Corporation Private Limited., GSK plc, and others.

Recent Developmental Activities in the Antipsychotic Drugs Market:

In November 2022, Teva Pharmaceuticals announced positive results for a Phase III trial on a subcutaneous, long-acting injectable risperidone formulation in the treatment of schizophrenia.

In November 2022, Neurocrine Biosciences partnered with Sosei Group Corporation to develop a new brand of protein inhibitor that helps to improve treatments for a wide range of neuropsychiatric disorders. Under the agreement, Neurocrine Biosciences has the right to develop and produce muscarinic M4, M1, and dual M1/M4 receptor agonists discovered by Sosei Heptares.

In February 2022, Dr. Reddy's Laboratories Ltd. launched Fluphenazine Hydrochloride Tablets, USP, a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, approved by the U.S. Food and Drug Administration (USFDA).

Key Takeaways from the Antipsychotic Drugs Market Report Study

  • Market size analysis for current antipsychotic drugs market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the antipsychotic drugs market.
  • Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the global antipsychotic drugs market.
  • Various opportunities available for the other competitor in the antipsychotic drugs market space.
  • What are the top-performing segments in 2023? How these segments will perform in 2030.
  • Which are the top-performing regions and countries in the current antipsychotic drugs market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for antipsychotic drugs market growth in the coming future?

Target Audience who can be benefited from this Antipsychotic Drugs Market Report Study

  • Antipsychotic drugs providers
  • Research organizations and consulting companies
  • Antipsychotic drugs -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in antipsychotic drugs
  • Various end users who want to know more about the antipsychotic drugs market and the latest developments in the antipsychotic drugs market.

Frequently Asked Questions for the Antipsychotic Drugs Market:

1. What are antipsychotic drugs?

Antipsychotic drugs are prescribed as short or long-term treatment of mental health problems. These drugs help alleviate and control psychotic symptoms such as anxiety, depression, delusions, hallucinations, or mania.

2. What is the global market for antipsychotic drugs?

The global antipsychotic drugs market was valued at USD 13,404.76 million in 2022 and is likely to register a CAGR of 6.62% during the forecast period from 2024 to 2030 to reach USD 19,653.29 million by 2030.

3. What are the drivers for the global antipsychotic drugs market?

The antipsychotic drugs market is witnessing positive market growth owing to the factors such as the growing prevalence of mental disorders, increasing geriatric population base prone to mental related ailments, increasing focus of governments and health care organizations on mental health, growing demand of long-acting injectables, surging new drug launches and approvals, presence of key players in the market, and others will create an exigency for the antipsychotic drugs market.

4. Who are the key players operating in the global antipsychotic drugs market?

Some of the key market players operating in the antipsychotic drugs market include Eli Lily and Company, Janssen Global Services, LLC, Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Alkermes, Inc., Dr. Reddy's Laboratories Ltd., AbbVie Inc., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., Alvogen., Hikma Pharmaceuticals PLC, Viatris Inc., Bayer AG, Bristol-Myers Squibb Company, Cardinal Health Inc., Sanis Health Inc., H. Lundbeck A/S, Elikem Pharmaceuticals Pvt Ltd, Devlife Corporation Private Limited., GSK plc, and others.

5. Which region has the highest share of the antipsychotic drugs market?

Among all the regions, North America is estimated to hold a significant revenue share in the global antipsychotic drugs market. This can be ascribed to the increasing demand for antipsychotic drugs among the patients in the region owing to the increasing prevalence of various mental disorders such as depression, bipolar disorders, substance-induced psychoses, schizophrenia, and others. Further, the rising burden of geriatric patients and the presence of key domicile players in the region are the reasons which act as a supportive factor for the North America antipsychotic drugs market growth.

Table of Contents

1.Antipsychotic Drugs Market Report Introduction

2. Antipsychotic Drugs Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

4. Antipsychotic Drugs Market Key Factors Analysis

  • 4.1. Antipsychotic Drugs Market Drivers
    • 4.1.1. Growing prevalence of mental disorders
    • 4.1.2. Increasing geriatric population base prone to mental related ailments
    • 4.1.3. Increasing focus of governments and health care organizations on mental health
    • 4.1.4. Increasing demand for long-acting injectable
  • 4.2. Antipsychotic Drugs Market Restraints and Challenges
    • 4.2.1. High cost of drug development and launches
    • 4.2.2. Addiction caused due to antipsychotic drugs
    • 4.2.3. The stringent regulatory approval process
  • 4.3. Antipsychotic Drugs Market Opportunities
    • 4.3.1. Availability of a robust product portfolio of antipsychotic drugs in various emerging countries
    • 4.3.2. Increasing investments in R&D activities of antipsychotic drugs

5. Antipsychotic Drugs Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Antipsychotic Drugs Market

7. Antipsychotic Drugs Market Layout

  • 7.1. By Indication
    • 7.1.1. Schizophrenia
    • 7.1.2. Bipolar Disorder
    • 7.1.3. Unipolar Disorder
    • 7.1.4. Dementia
    • 7.1.5. Others
  • 7.2. By Drug Class
    • 7.2.1. First-Generation or Typical Antipsychotics
      • 7.2.1.1. Haloperidol
      • 7.2.1.2. Prochloraperazine
      • 7.2.1.3. Others
    • 7.2.2. Second-Generation or Atypical Antipsychotics
      • 7.2.2.1. Clozapine
      • 7.2.2.2. Risperidone
      • 7.2.2.3. Others
    • 7.2.3. Third Generation
      • 7.2.3.1. Abilify (Aripiprazole)
      • 7.2.3.2. Others
  • 7.3. By Distribution Channel
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail Pharmacy
    • 7.3.3. E-commerce
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Antipsychotic Drugs Market in USD million (2021-2030)
      • 7.4.1.2. Canada Antipsychotic Drugs Market in USD million (2021-2030)
      • 7.4.1.3. Mexico Antipsychotic Drugs Market in USD million (2021-2030)
    • 7.4.2. Europe
      • 7.4.2.1. France Antipsychotic Drugs Market in USD million (2021-2030)
      • 7.4.2.2. Germany Antipsychotic Drugs Market in USD million (2021-2030)
      • 7.4.2.3. United Kingdom Antipsychotic Drugs Market in USD million (2021-2030)
      • 7.4.2.4. Italy Antipsychotic Drugs Market in USD million (2021-2030)
      • 7.4.2.5. Spain Antipsychotic Drugs Market in USD million (2021-2030)
      • 7.4.2.6. Rest of Europe Antipsychotic Drugs Market in USD million (2021-2030)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Antipsychotic Drugs Market in USD million (2021-2030)
      • 7.4.3.2. Japan Antipsychotic Drugs Market in USD million (2021-2030)
      • 7.4.3.3. India Antipsychotic Drugs Market in USD million (2021-2030)
      • 7.4.3.4. Australia Antipsychotic Drugs Market in USD million (2021-2030)
      • 7.4.3.5. South Korea Antipsychotic Drugs Market in USD million (2021-2030)
      • 7.4.3.6. Rest of Asia Pacific Antipsychotic Drugs Market in USD million (2021-2030)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Antipsychotic Drugs Market in USD million (2021-2030)
      • 7.4.4.2. Africa Antipsychotic Drugs Market in USD million (2021-2030)
      • 7.4.4.3. South America Antipsychotic Drugs Market in USD million (2021-2030)

8. Antipsychotic Drugs Market Company and Product Profiles

  • 8.1. Eli Lily and Company
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Janssen Global Services, LLC,
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Pfizer Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Otsuka Pharmaceutical Co., Ltd.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Alkermes, Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Dr. Reddy's Laboratories Ltd.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. AbbVie Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Sun Pharmaceutical Industries Ltd.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Amneal Pharmaceuticals LLC.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Alvogen.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Hikma Pharmaceuticals PLC
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Viatris Inc.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Bayer AG
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Bristol-Myers Squibb Company
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Cardinal Health Inc.
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Sanis Health Inc.
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. H. Lundbeck A/S
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Elikem Pharmaceuticals Pvt Ltd
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Devlife Corporation Private Limited.
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. GSK plc.
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us